Investigating cell-free DNA in acute stroke patients
CANTO - Cell-free DNA in Acute Stroke
This study looks at how cell-free DNA in the blood of patients with a severe type of stroke can help us understand the cause of their stroke and how well they respond to treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Basel, Switzerland Academic / other |
| Locations | 1 site (Basel) |
| Trial ID | NCT06928675 on ClinicalTrials.gov |
What this trial studies
This observational study aims to explore the role of cell-free DNA (cfDNA) in patients experiencing acute ischemic stroke due to large vessel occlusion. Researchers will analyze cfDNA in the hyperacute phase of stroke using blood and thrombus samples to understand its relationship with stroke etiologies, procedural factors like secondary embolization, and reperfusion outcomes. The study will also investigate the correlation between cfDNA content in blood and thrombus and identify the specific sources of cfDNA in different stroke subtypes.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older who have experienced an acute ischemic stroke due to large vessel occlusion and require mechanical thrombectomy.
Not a fit: Patients currently undergoing immunological therapies, those with immunological diseases, or systemic infections at the time of admission may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance understanding of stroke mechanisms and improve treatment strategies for acute ischemic stroke.
How similar studies have performed: While the role of cfDNA in various conditions has been explored, this specific investigation in acute stroke is novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Acute ischemic stroke due to large vessel occlusion (LVO) who require mechanical thrombectomy (detected in CT-Scan or MRI-Scan) * 18 years of age Exclusion Criteria: * Patients currently undergoing immunological therapies. * Patients with immunological diseases * Patients with systemic infections at the time of admission
Where this trial is running
Basel
- University Hospital Basel — Basel, Switzerland (Recruiting)
Study contacts
- Principal investigator: Gerrit Grosse, PD Dr. Dr. — University Hospital, Basel, Switzerland
- Study coordinator: Gerrit Grosse, PD Dr. Dr.
- Email: gerrit.grosse@usb.ch
- Phone: +41 61 32 85265
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.